Gastrins and gastrinomas

Hansky, J.

doi:10.1136/pgmj.60.709.767

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1986

1994

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastrin-34 is the major component in fasting serum with equal amounts. being released in response to food, whereas the gastric antrum contains predominantly gastrin-17 (29). In the study by Westerveld et al (27) the gastrin antiserum used bound all forms of gastrin with equimolar potency.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Pepsinogen A and Gastrin-17 as Markers of Gastric Cancer and High-Risk Pathologic Conditions

Hallissey

Dunn

Fielding

1994

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Pepsinogen A and Gastrin-17 as Markers of Gastric Cancer and High-Risk Pathologic Conditions

Hallissey

Dunn

Fielding

1994

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Surgery for peptic ulceration associated with hypergastrinaemia

Clark

Chowcat

Lewin

et al. 1986

Journal of British Surgery

View full text Add to dashboard Cite

Between 1971 and 1983, 31 males and 13 females were found to have peptic ulceration associated with hypergastrinaemia. An antral G-cell lesion was present in 11 (25 per cent) and a gastrinoma in 14 (32 per cent). There were 11 patients with multiple endocrine adenomatosis (MEA) (25 per cent) and 4 (9 per cent) with primary hyperparathyroidism. Four patients (9 per cent) were unclassified. Length of history and level of gastrin did not differentiate between the groups and an average of 2.5 operations was performed per patient, while the overall mortality was 27.3 per cent. The patients with G-cell lesions were significantly younger than all the other groups (P less than 0.01). Partial gastrectomy adequately treated G-cell hyperplasia. Total gastrectomy was required to treat pancreatic gastrinomata but additional pancreatic resection did not improve the outcome. In MEA, parathyroidectomy did not influence the treatment of a gastrinoma. This is the first recorded experience of surgery for hypergastrinaemia in the United Kingdom and the outcome of such a retrospective study may be a guide to the future management of these conditions.

show abstract